Branding Webinar 1


Transplant Service and Allied Health Talk

Tuesday, 9th April 2024 |  12.00PM - 1.30PM (UTC+8 | SGT)  |  Check your Time Zone


On Tuesday, April 9th, from 12:00 PM to 1:30 PM, we will be hosting a hybrid event featuring talks by Dr Melissa Gabriel and Ms Rebecca Fisher from The Children's Hospital at Westmead, Australia. 

Dr Melissa Gabriel will discuss the use of Viral Specific T cells in her HSCT programme, while Ms Rebecca Fisher will speak on the monitoring of micronutrients and bioimpedance during HSCT and Oncology treatment. Additionally, we also invite allied health teams and dieticians involved in oncology/BMT to join the discussion. Stay tuned for what promises to be an insightful and informative event.

If you can't make it, you can still register to receive a copy of the webinar recording.

Medical professionals in Singapore may eligible for CME/CPE/CNE credits for attending this event.
Credits and Certificates of Attendance will only be issued for those who are able to attend the live session and are in adherence with VIVA's Attendance Policy.



Using Viral Specific T Cells in HSCT Programme

Dr Melissa Gabriel will present the experience of using both donor derived and third party viral specific T cells over the past 20 years in our service. This is both bone marrow transplant patients and more recently in solid organ transplant patients.


Monitoring Micronutrients and the Use of Bio Impedance Analysis in Paediatric Patients Undergoing HSCT at The Children’s Hospital at Westmead

The Children’s Hospital at Westmead (CHW) introduced routine screening of micronutrients for HSCT patients in 2006. Paediatric patients undergoing HSCT are at risk of micronutrient deficiencies due to poor intake, nausea, vomiting, mucositis and other gastrointestinal complications. Identification and treatment of abnormal micronutrient levels is important for patient health.

Traditional anthropometric measurements (weight, height and body mass index) provide information of limited value in paediatric patients undergoing (HSCT). Bio Impedance Analysis (BIA) to measure body composition and fluid status was introduced at CHW in 2023. BIA as part of routine surveillance of patients provides additional information can be used to inform clinical decisions and treatment options. Ongoing monitoring of body composition helps to tailor clinical care including nutrition and fluid management, improving health outcomes.



Screenshot 2024 04 04 092555


Transplant Service and Allied Health Talk



Prof Kontny Udo

Dr Melissa Gabriel

Head, Oncology Survivorship Clinic
Caner Centre for Children, Children’s Hospital at Westmead





Dr Calvin Hoo

Ms Rebecca Fischer

Senior Clinical Dietitian
Children’s Hospital at Westmead




Prof Godfrey Chan

Dr Michaela Seng

Senior Consultant
Department of Paediatric Haematology and Oncology
KK Women's and Children's Hospital